NCT00118287View on ClinicalTrials.gov

Azacitidine and Etanercept in Treating Patients With Myelodysplastic Syndromes

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

October 31, 2008

Conditions
de Novo Myelodysplastic SyndromesPreviously Treated Myelodysplastic SyndromesSecondary Myelodysplastic Syndromes
Interventions
DRUG

azacitidine

Given SC or IV

BIOLOGICAL

etanercept

Given SC

Trial Locations (1)

98109

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Fred Hutchinson Cancer Center

OTHER

NCT00118287 - Azacitidine and Etanercept in Treating Patients With Myelodysplastic Syndromes | Biotech Hunter | Biotech Hunter